LB
Clinical-stage biotech developing AI-driven metabolic immunotherapies for cancer and autoimmune diseases.
About
Leman Biotech is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies through metabolic reprogramming. Their proprietary META 10 platform aims to reverse T cell exhaustion, a key bottleneck in immunotherapy efficacy. The company leverages AI and metabolic reprogramming to create cell therapies with improved safety, efficacy, and accessibility.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Leman Biotech do?
Leman Biotech is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies through metabolic reprogramming. Their proprietary META 10 platform aims to reverse T cell exhaustion, a key bottleneck in immunotherapy efficacy. The company leverages AI and metabolic reprogramming to create cell therapies with improved safety, efficacy, and accessibility.
How much funding has Leman Biotech raised?
Leman Biotech has raised a total of $23M in funding. The most recent round on record is Series A.
Where is Leman Biotech headquartered?
Leman Biotech is headquartered in Shenzhen, China.
When was Leman Biotech founded?
Leman Biotech was founded in 2021.
What industry does Leman Biotech operate in?
Leman Biotech operates in Biotech, HealthTech, Drug Discovery, Immunotherapy, CAR-T, Cell Therapy.